| Product vision |
- Uncomplicated malaria treatment and resistance management
|
| MoA |
|
| Key features |
- No cross-resistance
- No resistant mutants identified
- Low predicted dose (<100 mg) and long predicted half-life in human
- Fast killing in vitro and in vivo
|
| Challenges |
|
| Status |
- Good Laboratory Practice (GLP) toxicology studies ongoing
- Salt screen underway to develop final form
|
| Next milestone |
- Completion of Good Laboratory Practice (GLP) toxicology programme
|
| MMV Project Director |
|
